Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China's Sanpower Acquires Dendreon for $820 Million

publication date: Jan 10, 2017
Sanpower Group, a China conglomerate, paid $820 million to acquire Dendreon, which makes Provenge, the world's first immunotherapy, from Valeant Pharma. Approved as a treatment for prostate cancer in 2010, Dendreon never lived up to expectations because it combined high cost, limited insurance approvals and mediocre improvement over competitors. Its annual revenues are around $320 million. Based in Nanjing, Sanpower is involved in several industries, including healthcare delivery, though it hasn't previously produced pharmaceuticals. According to Sanpower, it has controlling interests in over 100 companies. More details....

Stock Symbol: (NYSE/TSX: VRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital